CONSIDERATIONS | ARISTOTLE, N = 18 201 | RELY, N = 18 113 | ROCKET-AF, N = 14 264 |
---|---|---|---|
Interventions |
|
|
|
Inclusion criteria |
|
|
|
Exclusion criteria |
|
|
|
CHADS2 score |
|
|
|
TTR | 66% | 64% | 55% |
Highlights |
|
|
|
AF—atrial fibrillation, APPRAISE—Apixaban for Prevention of Acute Ischemic Events, ARISTOTLE—Apixaban for Reduction in Stroke and Other ThromboemboLic Events in AF, ASA—acetylsalicylic acid, CAD—coronary artery disease, CrCl—creatinine clearance, CYP—cytochrome P450, DM—diabetes mellitus, GI—gastrointestinal, HF—heart failure, HTN—hypertension, INR—international normalized ratio, LVEF—left ventricular ejection fraction, MI—myocardial infarction, NNT—number needed to treat, NSAID—nonsteroidal anti-inflammatory drugs, NYHA—New York Heart Association, RELY—Randomized Evaluation of Long-term Anticoagulation Therapy, ROCKET-AF—Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonist for Prevention of Stroke and Embolism Trial in AF, TIA—transient ischemic attack, TTR—time in therapeutic range for patients taking warfarin.
↵* Dabigatran 110 mg twice daily and rivaroxaban were noninferior to warfarin for the primary end point; however, neither agent produced a statistically significant difference, compared with warfarin, when assessing the effect on stroke only. It should be noted this was a secondary outcome and neither trial was powered for this end point but interesting nonetheless.
Data from Granger et al,10 Connolly et al,11 Patel et al,12 and Alexander et al.13 Trial summaries14,15,16 of the 3 landmark trials are available from CFPlus.